Welcome to LookChem.com Sign In|Join Free
  • or
(5-amino-2-butylbenzofuran-3-yl)-[4-(2-cyanoethoxy)phenyl]methanone is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1401355-75-6

Post Buying Request

1401355-75-6 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1401355-75-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1401355-75-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,1,3,5 and 5 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1401355-75:
(9*1)+(8*4)+(7*0)+(6*1)+(5*3)+(4*5)+(3*5)+(2*7)+(1*5)=116
116 % 10 = 6
So 1401355-75-6 is a valid CAS Registry Number.

1401355-75-6Relevant academic research and scientific papers

REDUCTIVE AMINATION PROCESS FOR PREPARATION OF DRONEDARONE USING AMINE INTERMEDIARY COMPOUND

-

Paragraph 0152-0155, (2014/02/16)

The invention relates to a novel process for preparation of drohedarone of formula (I) and pharmaceutically acceptable salts thereof characterized in that a compound of formula (II) is reacted in the presence of a reductive agent with butyraldehyde and/or butanoic acid, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. The invention also relates to some hovel intermediary compounds and the preparation thereof.

PROCESS FOR PREPARATION OF DRONEDARONE BY N-BUTYLATION

-

Paragraph 0110-0113, (2014/05/07)

The invention relates to a novel process for preparation of dronedarone (I) and pharmaceutically acceptable salts thereof where the compound of formula (II) or salt thereof is reacted with a compound of formula L-(CH2)3—CH3 (III), where L is a leaving group, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. The invention also relates to some novel intermediary compounds and the preparation thereof.

REDUCTIVE AMINATION PROCESS FOR PREPARATION OF DRONEDARONE USING CARBOXYL INTERMEDIARY COMPOUND

-

Page/Page column 14, (2013/03/26)

The invention relates to a novel process for preparation of dronedarone of formula (I) and pharmaceutically acceptable salts thereof : Formula (I) characterized in that a compound of formula (II) : Formula (II) is aminated with compound of formula (III) among reductive conditions, : Formula (III) and the obtained product is isolated and, if desired, converted into a pharmaceutically acceptable salt thereof. The invention also relates to some novel intermediary compounds and the preparation thereof.

PROCESS FOR PREPARATION OF DRONEDARONE USING AMIDE INTERMEDIARY COMPOUND

-

Page/Page column 22, (2013/03/26)

The invention relates to a novel process for preparation of dronedarone of formula (I) and pharmaceutically acceptable salts thereof characterized in that the compound of formula (II) is reduced, and the obtained product is isolated and, if desired, converted into a pharmaceutically acceptable salt thereof. The invention also relates to some novel intermediary compounds and the preparation thereof.

REDUCTIVE AMINATION PROCESS FOR PREPARATION OF DRONEDARONE USING AMINE INTERMEDIARY COMPOUND

-

Page/Page column 20, (2012/10/18)

The invention relates to a novel process for preparation of drohedarone of formula (I) and pharmaceutically acceptable salts thereof characterized in that a compound of formula (II) is reacted in the presence of a reductive agent with butyraldehyde and/or butanoic acid, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. The invention also relates to some hovel intermediary compounds and the preparation thereof.

PROCESS FOR PREPARATION OF DRONEDARONE BY N-BUTYLATION

-

Page/Page column 16-17, (2012/10/18)

The invention relates to a novel process for preparation of dronedarone (I) and pharmaceutically acceptable salts thereof where the compound of formula (II) or salt thereof is reacted with a compound of formula L-(CH2)3-CH3 (III), where L is a leaving group, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. The invention also relates to some novel intermediary compounds and the preparation thereof.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1401355-75-6